Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19876252 | 0.97 | BTK (0.56) | BTKBRD4CYP11B1CYP11B2GSK3B | |
| SCHEMBL19876234 | 0.85 | BTK (0.57) | BTKBRD4GSK3BKCNH2 | |
| SCHEMBL19889750 | 0.83 | BTK (0.59) | BTKBRD4GSK3BKCNH2 | |
| SCHEMBL19878131 | 0.75 | BTK (0.67) | BTKBRD4KCNH2 | |
| SCHEMBL19889780 | 0.73 | BTK (1.00) | BTKKCNH2 | |
| SCHEMBL29598959 | 0.73 | BTK (1.00) | BTKKCNH2 | |
| SCHEMBL19876171 | 0.72 | BTK (0.47) | BTKBRD4F11 | |
| SCHEMBL21791244 | 0.72 | NOS3 (0.38) | BTKCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30104456 | 0.70 | BTK (0.48) | BTKKCNH2 | |
| SCHEMBL21791537 | 0.69 | BTK (0.37) | BTKCYP11B1CYP11B2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500569-B1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| CN-109641892-B | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | 默克专利有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | BTK, SYK, LCK | BTK 1/4885BRD4 85/4885CYP11B1 4208/4885 |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | BTK 1/4885BRD4 85/4885CYP11B1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.